Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

1,417 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Dapagliflozin decreases small dense low-density lipoprotein-cholesterol and increases high-density lipoprotein 2-cholesterol in patients with type 2 diabetes: comparison with sitagliptin.
Hayashi T, Fukui T, Nakanishi N, Yamamoto S, Tomoyasu M, Osamura A, Ohara M, Yamamoto T, Ito Y, Hirano T. Hayashi T, et al. Among authors: ohara m. Cardiovasc Diabetol. 2017 Jan 13;16(1):8. doi: 10.1186/s12933-016-0491-5. Cardiovasc Diabetol. 2017. PMID: 28086872 Free PMC article. Clinical Trial.
Combination Therapy with a Sodium-Glucose Cotransporter 2 Inhibitor and a Dipeptidyl Peptidase-4 Inhibitor Additively Suppresses Macrophage Foam Cell Formation and Atherosclerosis in Diabetic Mice.
Terasaki M, Hiromura M, Mori Y, Kohashi K, Kushima H, Ohara M, Watanabe T, Andersson O, Hirano T. Terasaki M, et al. Among authors: ohara m. Int J Endocrinol. 2017;2017:1365209. doi: 10.1155/2017/1365209. Epub 2017 Mar 19. Int J Endocrinol. 2017. PMID: 28408925 Free PMC article.
Correction to: Dapagliflozin decreases small dense low-density lipoprotein-cholesterol and increases high-density lipoprotein 2-cholesterol in patients with type 2 diabetes: comparison with sitagliptin.
Hayashi T, Fukui T, Nakanishi N, Yamamoto S, Tomoyasu M, Osamura A, Ohara M, Yamamoto T, Ito Y, Hirano T. Hayashi T, et al. Among authors: ohara m. Cardiovasc Diabetol. 2017 Nov 13;16(1):149. doi: 10.1186/s12933-017-0608-5. Cardiovasc Diabetol. 2017. PMID: 29132354 Free PMC article.
Comparison of liraglutide plus basal insulin and basal-bolus insulin therapy (BBIT) for glycemic control, body weight stability, and treatment satisfaction in patients treated using BBIT for type 2 diabetes without severe insulin deficiency: A randomized prospective pilot study.
Yamamoto S, Hayashi T, Ohara M, Goto S, Sato J, Nagaike H, Fukase A, Sato N, Hiromura M, Tomoyasu M, Nakanishi N, Lee S, Osamura A, Yamamoto T, Fukui T, Hirano T. Yamamoto S, et al. Among authors: ohara m. Diabetes Res Clin Pract. 2018 Jun;140:339-346. doi: 10.1016/j.diabres.2018.03.032. Epub 2018 Mar 26. Diabetes Res Clin Pract. 2018. PMID: 29588170 Free article. Clinical Trial.
1,417 results